EUVIMEDEUVIMED entdecken
Crossref

Development and Characterization of Albumin-Based Nanoparticles for Sustained Release of Repaglinide

Rajat Saxena, Purohit Rangavitala, Soumik Chatterjee, Shumpenthung Ezung, Uriti Sri Venkatesh

International Journal of Multidisciplinary Science and Innovation · 2025

DOI: 10.62896/ijmsi.v1.i1.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Multidisciplinary Science and Innovation, 2025. Verfasst von Rajat Saxena und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study focuses on the development and characterization of repaglinide-loaded albumin nanoparticles for sustained drug release, aimed at improving the management of Type 2 diabetes. The nanoparticles were synthesized using a solvent evaporation method, resulting in uniform particle size (150 ± 5 nm) with a low polydispersity index (PDI) of 0.23, and a negative zeta potential of -20 ± 1 mV, ensuring colloidal stability. The drug loading capacity and encapsulation efficiency were 4.5 ± 0.2% and 75 ± 3%, respectively. In vitro release studies demonstrated a controlled drug release profile, with 80 ± 8% of repaglinide released over 48 hours, suggesting potential for reducing dosing frequency and enhancing patient compliance. Kinetic analysis revealed that the release followed a Fickian diffusion mechanism (R² = 0.982). The nanoparticles showed good stability over 30 days, with only slight increases in particle size and PDI. Additionally, cytotoxicity studies confirmed the biocompatibility of the nanoparticles. Comparative analysis with other drug delivery systems showed that albumin nanoparticles offer superior controlled release and drug encapsulation efficiency, making them a promising alternative for repaglinide delivery in diabetes management. Further clinical validation is required for realworld applications.

Zitieren

APA

Saxena, R., Rangavitala, P., Chatterjee, S., Ezung, S., & Venkatesh, U. S. (2025). Development and Characterization of Albumin-Based Nanoparticles for Sustained Release of Repaglinide. International Journal of Multidisciplinary Science and Innovation. https://doi.org/10.62896/ijmsi.v1.i1.01

Vancouver

Saxena R, Rangavitala P, Chatterjee S, Ezung S, Venkatesh US. Development and Characterization of Albumin-Based Nanoparticles for Sustained Release of Repaglinide. International Journal of Multidisciplinary Science and Innovation. 2025. doi:10.62896/ijmsi.v1.i1.01

BibTeX
@article{Saxena2025,
  author = {Saxena, Rajat and Rangavitala, Purohit and Chatterjee, Soumik and Ezung, Shumpenthung and Venkatesh, Uriti Sri},
  title = {Development and Characterization of Albumin-Based Nanoparticles for Sustained Release of Repaglinide},
  journal = {International Journal of Multidisciplinary Science and Innovation},
  year = {2025},
  doi = {10.62896/ijmsi.v1.i1.01}
}
Kostenlos starten →